Cargando…

Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study

BACKGROUND: The efficacy of neuraminidase inhibitors on improvement of respiratory symptoms triggered by influenza in patients with pre‐existing chronic respiratory diseases is unknown. METHODS: This 2‐week, randomized, open‐label study evaluated intravenous peramivir 600 mg on two consecutive days...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Motokazu, Saisho, Yutaka, Tanaka, Hiroshi, Bando, Takuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767948/
https://www.ncbi.nlm.nih.gov/pubmed/32677375
http://dx.doi.org/10.1111/irv.12788
_version_ 1783629074930860032
author Kato, Motokazu
Saisho, Yutaka
Tanaka, Hiroshi
Bando, Takuma
author_facet Kato, Motokazu
Saisho, Yutaka
Tanaka, Hiroshi
Bando, Takuma
author_sort Kato, Motokazu
collection PubMed
description BACKGROUND: The efficacy of neuraminidase inhibitors on improvement of respiratory symptoms triggered by influenza in patients with pre‐existing chronic respiratory diseases is unknown. METHODS: This 2‐week, randomized, open‐label study evaluated intravenous peramivir 600 mg on two consecutive days (peramivir‐repeat), peramivir 300 mg single dose (peramivir‐single), and oral oseltamivir 75 mg twice daily for 5 days in patients with confirmed influenza and chronic respiratory diseases. Patients recorded symptom scores daily. The primary endpoint of cumulative area of time vs symptoms (CATVS) was expressed as an index value of area under the curve vs time of the total score of cough, sore throat, and nasal congestion from baseline to 2 weeks. RESULTS: Of 214 randomized patients, 209 (56% female, 77% aged <65 years, 94% outpatients, 91% bronchial asthma, 62% influenza A) received ≥1 dose of study drug. Mean (standard deviation) CATVS was similar for peramivir‐repeat (782.78 [487.17]) vs peramivir‐single (717.35 [347.55]; P = .4371), and for peramivir‐repeat vs oseltamivir (856.34 [404.99]; P = 1.00). However, CATVS was significantly shorter for peramivir‐single vs oseltamivir, with an estimated treatment difference (TD) of −145.07 (95% confidence interval: −284.57, −5.56; P = .0416). In subgroup analyses, CATVS was significantly shorter for peramivir‐single vs oseltamivir among patients with influenza A (TD: −206.31 [−383.86, −28.76]; P = .0231), bronchial asthma (TD: −156.57 [−300.22, −12.92]; P = .0328), baseline respiratory severity score <5 (TD: −265.32 [−470.42, −60.21]; P = .0120), and age <65 (TD: −184.30 [−345.08, −23.52]; P = .0249). CONCLUSIONS: In patients with chronic respiratory diseases, peramivir‐single was not significantly different from peramivir‐repeat and was more effective than oseltamivir at alleviating respiratory symptoms.
format Online
Article
Text
id pubmed-7767948
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77679482021-01-01 Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study Kato, Motokazu Saisho, Yutaka Tanaka, Hiroshi Bando, Takuma Influenza Other Respir Viruses Original Articles BACKGROUND: The efficacy of neuraminidase inhibitors on improvement of respiratory symptoms triggered by influenza in patients with pre‐existing chronic respiratory diseases is unknown. METHODS: This 2‐week, randomized, open‐label study evaluated intravenous peramivir 600 mg on two consecutive days (peramivir‐repeat), peramivir 300 mg single dose (peramivir‐single), and oral oseltamivir 75 mg twice daily for 5 days in patients with confirmed influenza and chronic respiratory diseases. Patients recorded symptom scores daily. The primary endpoint of cumulative area of time vs symptoms (CATVS) was expressed as an index value of area under the curve vs time of the total score of cough, sore throat, and nasal congestion from baseline to 2 weeks. RESULTS: Of 214 randomized patients, 209 (56% female, 77% aged <65 years, 94% outpatients, 91% bronchial asthma, 62% influenza A) received ≥1 dose of study drug. Mean (standard deviation) CATVS was similar for peramivir‐repeat (782.78 [487.17]) vs peramivir‐single (717.35 [347.55]; P = .4371), and for peramivir‐repeat vs oseltamivir (856.34 [404.99]; P = 1.00). However, CATVS was significantly shorter for peramivir‐single vs oseltamivir, with an estimated treatment difference (TD) of −145.07 (95% confidence interval: −284.57, −5.56; P = .0416). In subgroup analyses, CATVS was significantly shorter for peramivir‐single vs oseltamivir among patients with influenza A (TD: −206.31 [−383.86, −28.76]; P = .0231), bronchial asthma (TD: −156.57 [−300.22, −12.92]; P = .0328), baseline respiratory severity score <5 (TD: −265.32 [−470.42, −60.21]; P = .0120), and age <65 (TD: −184.30 [−345.08, −23.52]; P = .0249). CONCLUSIONS: In patients with chronic respiratory diseases, peramivir‐single was not significantly different from peramivir‐repeat and was more effective than oseltamivir at alleviating respiratory symptoms. John Wiley and Sons Inc. 2020-07-17 2021-01 /pmc/articles/PMC7767948/ /pubmed/32677375 http://dx.doi.org/10.1111/irv.12788 Text en © 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Kato, Motokazu
Saisho, Yutaka
Tanaka, Hiroshi
Bando, Takuma
Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
title Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
title_full Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
title_fullStr Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
title_full_unstemmed Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
title_short Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: Findings of a randomized, open‐label study
title_sort effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre‐existing chronic respiratory disease: findings of a randomized, open‐label study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767948/
https://www.ncbi.nlm.nih.gov/pubmed/32677375
http://dx.doi.org/10.1111/irv.12788
work_keys_str_mv AT katomotokazu effectofperamivironrespiratorysymptomimprovementinpatientswithinfluenzavirusinfectionandpreexistingchronicrespiratorydiseasefindingsofarandomizedopenlabelstudy
AT saishoyutaka effectofperamivironrespiratorysymptomimprovementinpatientswithinfluenzavirusinfectionandpreexistingchronicrespiratorydiseasefindingsofarandomizedopenlabelstudy
AT tanakahiroshi effectofperamivironrespiratorysymptomimprovementinpatientswithinfluenzavirusinfectionandpreexistingchronicrespiratorydiseasefindingsofarandomizedopenlabelstudy
AT bandotakuma effectofperamivironrespiratorysymptomimprovementinpatientswithinfluenzavirusinfectionandpreexistingchronicrespiratorydiseasefindingsofarandomizedopenlabelstudy